Nymox Pharmaceutical Corporation (NYMX) Social Stream

Featured Post From StockTwits About NYMX

$NYMX Rough summer, but gotta buy this fade. Next 6 weeks company should finally file the NDA/MAA for their one-shot treatment for enlarged prostate. Great efficacy lasts for years, reinjectable, reduces need for surgey, improves sexual function, and showed a remarkable ~80% reduction in incidence of prostate cancer. And no side effects. Competing drugs have a Black Box warning they may CAUSE PCa. There are an estimated 21M actively managed patients in the US and EU. So figure 10% share at $4k per dose would be $8.4B peak revs. And just 1X revs is a $100 stock. $TFX owns UroLift and projects 60M patients in APAC and 30M in the broader EMEA market, but are not included in my projections. Also at some point the company should initiate P3 PCa trials, which could add further to the valuation. Best risk/reward in biotech imho. Glta longs!

What Else are NYMX Traders Talking About?

Other tickers frequently mentioned alongside NYMX is TFX.